← board
SANA
Sana Biotechnologydistress 7/10 · high distress / dilution risk$3.09-1%today-48% from 52w high
Oncology 2
Lead: type 1 diabetes · est. market ~$70B (approx, global)
Revenue
pre-revenue
Liquidity
$107M
Runway
0.8 yrs
Shares 1y
+17%
Price & events
-38.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.0%
1D
-2.5%
1W
-7.8%
1M
-10.2%
3M
-36.0%
6M
-39.9%
1Y
-50.9%
2Y
-83.4%
5Y
-91.2%
All
Overview
- Market Cap
- $859.92M
- Volume
- 211.93K
- 52 Week Range
- $2.68 – $5.92
- Total Shares
- 278.29M
- Float Shares
- 177.72M
- Short %
- 24.76%
- % Held by Insiders
- 6.51%
- % Held by Institutions
- 82.83%
- RVOL
- 0.07x
- Beta
- 2.14
Pipeline stages · 2 programs
SC262
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
SC291
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
Catalyst news & presentations · 13
- next 12-18 monthsGuided 55%readoutSC451 · Initial clinical dataSEC 8-K
- next 12-18 monthsGuided 55%readoutSG293 · Initial clinical dataSEC 8-K
- as early as 2026Guided 40%regulatory submissionFiled (NDA/BLA)SC451 · IND filing expectedSEC 8-K
- as early as 2026Guided 40%regulatory submissionFiled (NDA/BLA)SG299 · IND filing expectedSEC 8-K
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-04-10partnershipSC451 · Stock purchase agreement and license agreement with Mayo Clinic to fund development of SC451 and genetically modified stem-cell derived islet cell products.SEC 8-K
- as early as 2026trial initiationsecondaryPhase 1SC451 · Begin Phase 1 trial for SC451SEC 8-K
- as early as 2026regulatory submissionFiled (NDA/BLA)SC451 · File IND for SC451SEC 8-K
- as early as 2026readoutPhase 1SG293 · Initial human data for SG293 in vivo CD19-directed CAR TSEC 8-K
- 2025readoutPhase 1SC262 · VIVID trial data expectedSEC 8-K
- 2025readoutPhase 1SC291 · GLEAM trial data expectedSEC 8-K
- as the year progressesreadoutUP421 · report longer-term follow-up dataSEC 8-K
- todayconferencedata presentationsecondaryUP421 · Six-month results presented at ADA Scientific SessionsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $9 (+177% upside) · 7 analysts
- 2026-04-14WedbushOutperform
- 2026-03-04HC Wainwright & Co.Buy
- 2026-01-06B of A SecuritiesBuy
- 2025-11-07WedbushOutperform
- 2025-11-07HC Wainwright & Co.Buy
- 2025-10-30CitizensMarket Outperform
Competitors — type 1 diabetes
- LLYELI LILLY & Co$1094.4B · D3
- VRTXVERTEX PHARMACEUTICALS INC / MA$119.1B · D1
- SNYSanofi$52.5B · D1
- NKTRNEKTAR THERAPEUTICS$2.3B · D8
- IMCRImmunocore Holdings plc$1.8B · D1
- MNKDMANNKIND CORP$1.2B · D0
- IPSCCentury Therapeutics, Inc.$381M · D6
- SABSSAB Biotherapeutics, Inc.$270M · D3
- BMEABiomea Fusion, Inc.$90M · D6
- CELZCREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.$3M · D7
Recent news
- 2026-07-22Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation - Seeking Alpha
- 2026-07-22Sana Biotechnology (SANA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
- 2026-07-21Iran Rejects Restrictions on Yemen Airspace, Condemns Strike on Sana’a Airport - Yemen Online
- 2026-07-21Iran Rejects Restrictions on Yemen Airspace, Condemns Strike on Sana’a Airport - Yemen Online
- 2026-07-20Sana heads to Tokyo in all-black athleisure - CHOSUNBIZ - Chosunbiz
- 2026-07-20Misa-mo's Sana, "Sana Flower Has Bloomed" [★Photo] - starnewskorea.com
- 2026-07-20Lazio 3-1 Lazio U20: Artistico & Sana Fernandes Score in First Summer Friendly - The Laziali
- 2026-07-20Yemen to React Decisively to Harassment of Planes Heading toward Sana’a - تسنیم
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.